FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| A feasibility study of scheduling a remission consultation in the management of patients treated for localized breast cancer. PMID 41024190 · BMC Psychol · 2025-Sep-29 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Evaluating the effectiveness of a risk prediction model (PERSARC) on improving treatment decisions quality for patients with soft-tissue sarcomas: the VALUE-PERSARC study. PMID 41023919 · BMC Med Inform Decis Mak · 2025-Sep-29 The study is an oncology randomized trial in humans, but it does not meet key eligibility criteria. It lacks a primary/key secondary time-to-event efficacy endpoint (the primary outcome is decision-making quality, not survival or progression). Furthermore, the intervention is a risk prediction model (PERSARC) to support decision-making, not a drug-containing intervention. The phase is also not explicitly stated as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer. PMID 41022779 · NPJ Breast Cancer · 2025-Sep-29 The record describes a biomarker analysis (tsMHC-II expression) from a phase III randomized trial (NeoTRIP). While it is oncology, human, randomized, phase III, and involves a drug intervention, the primary endpoint analyzed is pathological complete response (pCR), which is not a time-to-event endpoint. The report is a subgroup/biomarker analysis, not the primary trial report. Therefore, it does not meet the required criterion for a time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Lumateperone in depression associated with bipolar II disorder: a pooled analysis of late-phase clinical trials. PMID 41017591 · CNS Spectr · 2025-Sep-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trial. PMID 41016926 · Signal Transduct Target Ther · 2025-Sep-29 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of respiratory syncytial virus vaccines. PMID 41016728 · Cochrane Database Syst Rev · 2025-Sep-29 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Comparison of ultrasound-guided continuous intertransverse process block and continuous erector spinae plane block for postoperative analgesia after uniportal video-assisted thoracoscopic surgery: protocol for a double-blind, prospective, randomised controlled trial. PMID 41022450 · BMJ Open · 2025-Sep-28 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint. PMID 40651005 · J Crohns Colitis · 2025-Sep-28 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of preoperative immunonutrition vs standard oral nutrition in patients undergoing colorectal surgery: A randomized controlled trial. PMID 41024777 · World J Gastrointest Surg · 2025-Sep-27 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Alzheimer's disease outlook: controversies and future directions. PMID 40997840 · Lancet · 2025-Sep-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. PMID 40976249 · Lancet · 2025-Sep-27 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. PMID 40897189 · Lancet · 2025-Sep-27 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. PMID 40897188 · Lancet · 2025-Sep-27 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Therapeutic effect and mechanism of sivelestat sodium on acute lung injury: A randomized controlled trial. PMID 41029079 · Medicine (Baltimore) · 2025-Sep-26 The study is a randomized controlled trial of a drug (sivelestat sodium) for acute lung injury, not a human malignant neoplasm. It lacks a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) as required for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hypothermic oxygenated perfusion (HOPE) against cancer recurrence after liver transplantation for hepatocellular carcinoma-study protocol for an international multicenter randomized controlled trial (HOPE4Cancer). PMID 41013675 · Trials · 2025-Sep-26 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Re-emergence of circulating non-malignant B cells as a prognostic biomarker in chronic lymphocytic leukaemia. PMID 41006384 · Sci Rep · 2025-Sep-26 The record is a secondary biomarker analysis from a phase III trial. It is not the original formal report of the randomized trial's primary or key secondary efficacy results. Therefore, it does not meet the inclusion criteria for an original result report of a Phase III randomized trial with a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Racial Differences in Symptom Burden and Endocrine Therapy Adherence in Breast Cancer: A Post Hoc Analysis of a Randomized Trial. PMID 41005350 · J Natl Compr Canc Netw · 2025-Sep-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Treatment and recovery from opioid use disorder: The role of pain severity in individuals with moderate to severe pain. PMID 41046662 · Drug Alcohol Depend · 2025-Sep-25 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| School-based group interpersonal therapy for adolescents with depression in nepal: protocol for a phase III realist cluster-randomised controlled trial. PMID 40999412 · BMC Psychiatry · 2025-Sep-25 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Phase II randomised controlled basket feasibility trial of a personalised, remotely delivered exercise programme on disease-free survival among early-stage, high-risk cancers: CANFit study protocol. PMID 40998437 · BMJ Open · 2025-Sep-25 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke. PMID 40616232 · N Engl J Med · 2025-Sep-25 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. PMID 40521799 · N Engl J Med · 2025-Sep-25 The record explicitly describes a Phase 3 randomized trial of human CLL with drug interventions (ibrutinib-venetoclax, ibrutinib alone, FCR) and primary/secondary time-to-event efficacy endpoints (PFS with HR and KM estimates, OS with HR). It reports formal final results with statistical significance. All required criteria are explicitly established. |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis. PMID 40411449 · Clin Exp Dermatol · 2025-Sep-25 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant treatment in resectable pancreatic cancer: Why is upfront surgery so hard to be beaten? PMID 41024839 · World J Clin Oncol · 2025-Sep-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Prognostic immune nutritional index-based nutritional stratification enhances recovery and survival in gastric cancer: A randomized controlled trial. PMID 41024831 · World J Clin Oncol · 2025-Sep-24 The record describes a randomized controlled trial in gastric cancer evaluating PINI-based nutritional support. However, it does not meet key eligibility criteria: the phase is not specified as Phase III/IIIb or Phase II/III, the intervention is non-drug nutritional support, and the primary endpoint is not a time-to-event efficacy endpoint with Kaplan-Meier or HR analysis. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The IC3 trial: protocol for a multicentre individually randomised controlled trial to compare a cirrhosis detection and hepatocellular carcinoma surveillance pathway vs usual care in Australian general practice for 45-75 years old with risk factors for chronic liver disease. PMID 40993832 · Trials · 2025-Sep-24 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Caffeine to improve neurodevelopmental outcomes in infants born late preterm (The Latte Trial): study protocol for a randomised controlled trial. PMID 40993821 · Trials · 2025-Sep-24 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial. PMID 41096556 · Int J Mol Sci · 2025-Sep-23 The record is not an oncology study; it is a randomized controlled trial of curcumin for liver steatosis in Type 2 Diabetes. It lacks a drug-containing intervention per the criteria, does not have a primary time-to-event efficacy endpoint, and the phase is not established as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Preoperative short-course radiotherapy followed by chemotherapy and PD-1 inhibitor administration for locally advanced rectal cancer: the initial results of a randomized controlled clinical trial (STELLAR II)]. PMID 40967882 · Zhonghua Zhong Liu Za Zhi · 2025-Sep-23 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis. PMID 40674744 · Blood Adv · 2025-Sep-23 未发现恶性肿瘤人群证据。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of apixaban thrombosis prevention in pediatric patients with obesity and acute lymphoblastic leukemia. PMID 40505060 · Blood Adv · 2025-Sep-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Immune Checkpoint Inhibitors Beyond Progression in Various Solid Tumors: A Systematic Review and Pooled Analysis. PMID 41010884 · J Clin Med · 2025-Sep-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Protocol for development of SPIRIT and CONSORT extensions for reporting climate and environmental outcomes in randomised trials (SPIRIT-ICE and CONSORT-ICE). PMID 40976669 · BMJ Open · 2025-Sep-21 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. PMID 40779733 · J Clin Oncol · 2025-Sep-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | confirmed 1 Figure · 1 Panel · risk visible |
| Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826. PMID 40523203 · J Clin Oncol · 2025-Sep-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 1 Figure · 1 Panel · risk unclear |
| Baseline Anti-SARS-CoV-2 IgG and Protection from Symptomatic Infection: Post Hoc Analysis of the SCTV01E Phase 3 Randomized Trial. PMID 41012186 · Vaccines (Basel) · 2025-Sep-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer. PMID 40961426 · N Engl J Med · 2025-Sep-18 Record meets all eligibility criteria: Phase III randomized trial in human oncology with drug intervention (aspirin) and primary time-to-event efficacy endpoint. |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. PMID 40544435 · N Engl J Med · 2025-Sep-18 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Current Clinical Trial Landscape of Gastroenteropancreatic Neuroendocrine Tumors: A New Era of Landmark Trials. PMID 41010726 · J Clin Med · 2025-Sep-17 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Tumour-Infiltrating Lymphocytes, Tumour Cell Density, and Response to Neoadjuvant Short-Course Radiotherapy in Rectal Cancer: A Translational Sub-Study from the MRC CR07 Clinical Trial. PMID 41008883 · Cancers (Basel) · 2025-Sep-17 The study is a translational sub-study of the MRC CR07 trial, analyzing biomarkers (TCD and TIL) in a randomized trial of radiotherapy versus surgery. The intervention does not contain a drug, and the report focuses on biomarker prognostic/predictive value, not the primary efficacy analysis of a drug-containing Phase III/IIIb or Phase II/III randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Rasch analysis of the NEI-VFQ-25: vision-related quality of life in Leber hereditary optic neuropathy after lenadogene nolparvovec gene therapy. PMID 40967677 · BMJ Open Ophthalmol · 2025-Sep-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Phenomapping-derived selection of fractional flow reserve or optical coherence tomography to personalise percutaneous coronary intervention. PMID 40967674 · Open Heart · 2025-Sep-17 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| High-precision radiotherapy achieves excellent long-term control and preserves function in pediatric craniopharyngioma-Subset analysis of a randomized trial. PMID 40056158 · Neuro Oncol · 2025-Sep-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Gut microbiome modulates the outcome in primary central nervous system lymphoma patients undergoing chemotherapy: An ancillary study from the BLOCAGE trial. PMID 40048707 · Neuro Oncol · 2025-Sep-17 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 3 Figure · 6 Panel · risk not_visible |
| Psychedelics for major depression-From controlled research settings into broader clinical use. PMID 40961925 · Cell Rep Med · 2025-Sep-16 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of benvitimod 1% cream for atopic dermatitis in patients aged 2 years and older: A phase III randomized clinical trial. PMID 40960153 · Chin Med J (Engl) · 2025-Sep-16 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical pharmacology and therapeutic applications of talazoparib: a comprehensive review. PMID 40956449 · Cancer Chemother Pharmacol · 2025-Sep-16 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| CHOSEN: A Randomized Controlled Feasibility Trial. PMID 40932100 · J Am Heart Assoc · 2025-Sep-16 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial. PMID 40839372 · JAMA · 2025-Sep-16 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-Year follow-up of a randomized clinical trial. PMID 40795846 · Cell Rep Med · 2025-Sep-16 The study is an oncology randomized trial with a drug intervention (berberine) and reports original results on adenoma recurrence. However, the phase is not explicitly stated as Phase III/IIIb or Phase II/III; it is an extended follow-up of a previous trial, but the original trial's phase is not specified in the record. The primary endpoint is adenoma recurrence (a categorical outcome), not a time-to-event endpoint (OS, PFS, etc.) or Kaplan-Meier/HR analysis. Therefore, it fails the 'phase3_or_definitive' and 'time_to_event' criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |